The use of taxanes in choriocarcinoma; a case report and review of the literature.
BACKGROUND
Both preclinical data and case reports support the use of taxanes for high-risk metastatic choriocarcinoma.


METHODS
We report the case of a 31-year-old with metastatic choriocarcinoma who required 3rd-line treatment with a paclitaxel-cisplatin-based regimen. She achieved a complete response and remains relapse-free 21 months after her last dose of chemotherapy.


CONCLUSIONS
The literature suggests that paclitaxel contributes significantly to the treatment of choriocarcinoma and its use should be explored further. This is the first case report formally reporting its combination with cisplatin.
Joshua
A M
AM
Department of Medical Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Road, Campderdown 2050, Sydney, Australia.
Carter
J R
JR
Beale
P
P
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D017239:Paclitaxel; D002945:Cisplatin